Skip to main content
Equibles

BLTE · Belite Bio, Inc

Track BLTE — free

Use BLTE with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research BLTE.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$155.61 -3.57 (-2.24%)
Rebalance outlook locked
Market Cap
$6.71B
Shares
40.27M
Volume · Oct 6 190.28K Avg daily vol (3M) 183.26K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$159.18 Open$160.00 Day$156.40–160.00 52W close$77.40–193.61 Avg vol 30d193K Short int1.1M · 2.6% float · 3.8d Short vol68% Last earningsAug 13, 2026 DataApr 2022–Oct 2026

Up next

Next earnings call
Nov 9, 2026 Est · unconfirmed · in 5 wks
Q2 2026 earnings call transcript
call held Aug 13, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
+115.4%
Trailing year
Short interest
2.6%
Latest settlement · 3.8 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Neutral Momentum Very Weak Sentiment Neutral Fundamentals Poor Quant / Vol Very High
Market backdrop VIX 15.5 · calm Equity put/call 0.59
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg −1%
below
Price vs 50-day avg −4%
below
RSI (14) 41
neutral
MACD trend Negative
52-week position 70%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −18%
trailing
6-month return −7%
trailing
YTD return 0%
this year
Relative strength −19%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $166 › 200d $161 — 50d above 200d
Institutional flow Accumulating
+7% holders QoQ · +21 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
2.61% of float · ▲ +0.1% MoM · 3.8 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
80 holders — near 3-yr high, broad support
Squeeze score 52
elevated · 0–100
Fundamentals
Poor
EPS growth −96%
Y/Y
Free cash flow $-37.1M
Quant / Vol
risk profile
Very High
Volatility 54%
annualized · 1-yr
Max drawdown −29%
past year
ATR 4.1%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral
1 · 6 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−1% Neutral
Price vs 50-day avg
−4% Neutral
RSI (14)
41 Neutral
MACD trend
Negative Bearish
52-week position
70% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $166 › 200d $161 — 50d above 200d
Institutional flow Accumulating
+7% holders QoQ · +21 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
2.61% of float · ▲ +0.1% MoM · 3.8 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
80 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $77 Now $159 · 70% Range high $194
vs 200-day avg -1% vs 50-day avg -4%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
BLTE
Belite Bio, Inc
this stock
$6.71B -0.5% — — 2.6%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $133.37B +11.1% +46.2% 30.7 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
 $81.13B -5.9% +20.8% 19.5 2.5%
MRNA
Moderna, Inc.
 $79.40B +589.1% +4.3% — 8.2%
CSLLY
Csl Ltd
 $61.25B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
80
% held
23.5%
Net QoQ
+356.9K sh
Top holder
Darwin Global Management,…
Held Float
View
Held by Funds
Fund positions
22
View
Short & Settlement
Short Interest Rising
Shares short
1.1M
Days to cover
3.8d
Change
+649 sh
View
Short Volume
Short vol %
68%
As of
Oct 6, 2026
Short Total
View
Fails to Deliver
FTD shares
10.7K
Value
$2.1M
As of
Sep 8, 2026
View
Off-Exchange
Off-exchange %
50.4%
Week of
Aug 31, 2026
Off-exch Lit
View
Financials
Financials
Net income (FY)
$-77.6M
EPS diluted
$-2.31
View
Filings
SEC Filings
Latest
6-K
Filed
Sep 8, 2026
This year
10
View
Proposed Sales
Value
$1.2M
Shares
9.6K
Filed
Oct 17, 2025
View
Earnings & Events
Webcasts
Last webcast
Aug 13, 2026
View
Investor Relations
Upcoming events
1
View

Performance

5D 20D 120D MTD YTD
BLTE -4.1% -17.8% -7.4% -6.3% -0.5%
SPY +1.2% +0.6% +11.6% +1.6% +13.6%
vs SPY -5.3% -18.4% -19.0% -7.9% -14.1%
Key facts CIK 1889109 CUSIP 07782B104 13F (30d) 2 filings 2 filers Visit website Investor relations